Complement regulator CD46: Genetic variants and disease associations

Human Genomics

Volumn 9, Issue , 2015, Pages

  Kathryn Liszewski, M ^a   Atkinson, John P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical hemolytic uremic syndrome; CD46; Complement; Complement regulation; Membrane cofactor protein

Indexed keywords

COMPLEMENT; MEMBRANE COFACTOR PROTEIN;

COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; GENE CLUSTER; GENETIC VARIABILITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOMODULATION; PROTEIN FUNCTION; REVIEW;

EID: 85075591967     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/s40246-015-0029-z     Document Type: Review

References (84)

1. Zhu Y, Thangamani S, Ho B, Ding JL. The ancient origin of the complement system. EMBO J. 2005;24(2):382–94.
2. Ariki S, Takahara S, Shibata T, Fukuoka T, Ozaki A, Endo Y, et al. Factor C acts as a lipopolysaccharide-responsive C3 convertase in horseshoe crab complement activation. J Immunol. 2008;181 (11):7994–8001. doi:181/11/7994.
3. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184–92.
4. Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61(2):110–7. doi:10.1016/j.molimm.2014.06.030.
5. Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance of complement deficiencies. In: Shoenfeld Y, Gershwin ME, editors. Annals of the New York Academy of Sciences. Boston: Blackwell Publishing; 2009. p. 108–23.
6. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol. 1991;9:431–55.
7. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729–40. doi:10.1038/nri2620.
8. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433–59. doi:10.1146/annurev-immunol-032713-120154.
9. Mayilyan KR. Complement genetics, deficiencies, and disease associations. Protein & cell. 2012;3(7):487–96. doi:10.1007/s13238-012-2924-6.
10. Nonaka M, Kimura A. Genomic view of the evolution of the complement system. Immunogenetics. 2006;58(9):701–13.
11. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat Rev Immunol. 2008;8(1):48–58.
12. Walport MJ. Complement. First of two parts N Engl J Med. 2001;344(14):1058–66. doi:10.1056/NEJM200104053441406.
13. Tsujikura M, Nagasawa T, Ichiki S, Nakamura R, Somamoto T, Nakao M. A CD46-like molecule functional in teleost fish represents an ancestral form of membrane-bound regulators of complement activation. J Immunol. 2015;194(1):262–72. doi:10.4049/jimmunol.1303179.
14. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology.2010;215(1):1–11. doi:S0171-2985(09)00146-6 [pii] 10.1016/j.imbio.2009.08.006
15. Bubeck D. The making of a macromolecular machine: assembly of the membrane attack complex. Biochemistry (Mosc). 2014;53(12):1908–15. doi:10.1021/bi500157z.
16. Liszewski MK, Kemper C, Price JD, Atkinson JP. Emerging roles and new functions of CD46. Springer Semin Immunopathol. 2005;27(3):345–58.
17. Cardone J, Le Friec G, Kemper C. CD46 in innate and adaptive immunity: an update. Clin Exp Immunol. 2011;164(3):301–11. doi:10.1111/j.1365-2249.2011.04400.x.
18. Yamamoto H, Fara AF, Dasgupta P, Kemper C. CD46: the ‘multitasker’ of complement proteins. Int J Biochem Cell Biol. 2013;45(12):2808–20. doi:10.1016/j.biocel.2013.09.016.
19. Hourcade D, Holers VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381–416.
20. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol. 2006;118(2–3):127–36.
21. Rodriguez De Cordoba S, Goicoechea De Jorge E. Translational mini-review series on complement factor H: genetics and disease associations in human complement factor H. Clin Exp Immuno. 2008;151:1–13.
22. Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens’ magnet. J Virol. 2004;78(9):4385–8.
23. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol. 2007;7(1):9–18.
24. Kemper C, Atkinson JP. Measles virus and CD46. Curr Top Microbiol Immunol. 2009;329:31–57.
25. Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology. 2009;384(2):380–8. doi:10.1016/j.virol.2008.10.016.
26. Tang H, Mori Y. Human herpesvirus-6 entry into host cells. Future Microbiol. 2010;5(7):1015–23. doi:10.2217/fmb.10.61.
27. Weyand NJ, Calton CM, Higashi DL, Kanack KJ, So M. Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection. J Immuno. 2010;184(2):694––701. doi:10.4049/jimmunol.0900522. jimmunol.0900522.
28. Lovkvist L, Sjolinder H, Wehelie R, Aro H, Norrby-Teglund A, Plant L, et al. CD46 contributes to the severity of Group A streptococcal infection. Infect Immun. 2008;76(9):3951–8.
29. + T cells by streptococcal M protein. J Immunol. 2005;175:677–84.
30. Mahtout H, Chandad F, Rojo JM, Grenier D. Fusobacterium nucleatum binding to complement regulatory protein CD46 modulates the expression and secretion of cytokines and matrix metalloproteinases by oral epithelial cells. J Periodontol. 2011;82(2):311–9. doi:10.1902/jop.2010.100458.
31. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol. 2009;183:3150–9.
32. Ojha H, Panwar HS, Gorham Jr RD, Morikis D, Sahu A. Viral regulators of complement activation: structure, function and evolution. Mol Immunol. 2014;61(2):89–99. doi:10.1016/j.molimm.2014.06.004.
33. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, Wang X, et al. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol. 2006;176(6):3725–34.
34. Yadav VN, Pyaram K, Mullick J, Sahu A. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J Virol. 2008;82:3283–9.
35. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 2010;11(8):674–80. doi:10.1038/ni.1899.
36. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey M-A, Blouin J, Caudy A, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17:2017–25.
37. Fuchs A, Atkinson JP, Fremeaux-Bacchi V, Kemper C. CD46-induced human Treg enhance B-cell responses. Eur J Immunol. 2009;39(11):3097–109. doi:10.1002/eji.200939392.
38. Esparza-Gordillo J. Goicoechea De Jorge E, Buil A, Berges LC, Lopez-Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14(5):703–12.
39. Esparza-Gordillo J, Goicoechea De Jorge E, Buil A, Berges LC, Lopez-Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Gene. 2005;14(8):1107. CORRIGENDUM.
40. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V. Goicoechea De Jorge E, Goodship TH, Lopez Trascasa M, et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models Hum Mutat. 2007;28(3):222–34.
41. Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010;74(1):17–26. doi:10.1111/j.1469-1809.2009.00554.x.
42. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496–502. doi:10.1016/j.ejim.2013.05.009.
43. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508–30. doi:10.1016/j.semnephrol.2013.08.003.
44. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN, et al. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem. 2000;275(48):37692–701.
45. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31(6):E1445–60. doi:10.1002/humu.21256.
46. Rodriguez De Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40:422–30. doi:10.1055/s-0034-1375296.
47. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–79.
48. Richards A, Liszewski MK, Kavanagh D, Fang CJ, Moulton EA, Fremeaux-Bacchi V, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44:111–22.
49. Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014;40(4):444–64. doi:10.1055/s-0034-1376153.
50. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi:10.1186/1750-1172-6-60.
51. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003;100:12966–71.
52. Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362(9395):1542–7.
53. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V. Rodriguez De Cordoba S, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype J Am Soc Nephro. 2013;24(3):475–86. doi:10.1681/ASN.2012090884.
54. Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55–64. doi:10.1681/ASN.2013050453.
55. Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep. 2014;34(5):art:e00146. doi:10.1042/BSR20140117.
56. Scambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, La Verde V, et al. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study. PLoS One. 2015;10(2), e0114856. doi:10.1371/journal.pone.0114856.
57. Jonsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, et al. Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther. 2011;13(6):R206. doi:10.1186/ar3539.
58. Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJ, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25(11):2322–5. doi:10.3109/14767058.2012.694923.
59. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8(3), e1001013. doi:10.1371/journal.pmed.1001013.
60. Mohlin FC, Mercier E, Fremeaux-Bacchi V, Liszewski MK, Atkinson JP, Gris JC, et al. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol. 2013;43(6):1617–29. doi:10.1002/eji.201243196.
61. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008;111(2):624–32. doi:10.1182/blood-2007-04-084533.
62. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007;44(3):193–9.
63. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128(3):349–58. doi:10.1001/archophthalmol.2010.18. 128/3/349.
64. Khandhadia S, Cipriani V, Yates JR, Lotery AJ. Age-related macular degeneration and the complement system. Immunobiology. 2012;217(2):127–46. doi:10.1016/j.imbio.2011.07.019. S0171-2985(11) 00159-8.
65. Sobrin L, Seddon JM. Nature and nurture-genes and environment-predict onset and progression of macular degeneration. Prog Retin Eye Res. 2014;40:1–15. doi:10.1016/j.preteyeres.2013.12.004.
66. Schramm EC, Clark SJ, Triebwasser MP, Raychaudhuri S, Seddon JM, Atkinson JP. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol. 2014;61(2):118–25. doi:10.1016/j.molimm.2014.06.032.
67. Bora NS, Matta B, Lyzogubov VV, Bora PS. Relationship between the complement system, risk factors and prediction models in age-related macular degeneration. Mol Immunol. 2015;63(2):176–83. doi:10.1016/j.molimm.2014.07.012.
68. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81. doi:10.1056/NEJMoa1208981.
69. Provaznikova D, Rittich S, Malina M, Seeman T, Marinov I, Riedl M, et al. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol. 2012;27(1):73–81. doi:10.1007/s00467-011-1943-5.
70. Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol. 2013;54(2):238–46. doi:10.1016/j.molimm.2012.12.006.
71. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. CJASN. 2013;8(4):554–62. doi:10.2215/CJN.04760512.
72. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. CJASN. 2010;5(10):1844–59. doi:10.2215/CJN.02210310.
73. Reuter S, Heitplatz B, Pavenstadt H, Suwelack B. Successful long-term treatment of TMA with Eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation. Transplantation. 2013;96(10):e74–6. doi:10.1097/01.TP.0000435705.63428.1f.
74. Fremeaux-Bacchi V, Sanlaville D, Menouer S, Blouin J, Dragon-Durey MA, Fischbach M, et al. Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. Am J Kidney Dis. 2007;49(2):323–9. doi:10.1053/j.ajkd.2006.10.022.
75. Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant. 2009;24(9):2752–4. doi:10.1093/ndt/gfp166.
76. Reid VL, Mullan A, Erwig LP. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ case reports. 2013;2013(sep04 1):bcr2013200980–bcr2013200980. doi:10.1136/bcr-2013-200980.
77. Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, et al. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail. 2010;32(6):753–6. doi:10.3109/0886022×.2010.486491.
78. Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–67. doi:10.1681/ASN.2009070706.
79. Pabst WL, Neuhaus TJ, Nef S, Bresin E, Zingg-Schenk A, Sparta G. Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations. Pediatr Nephrol. 2013. doi:10.1007/s00467-013-2450-7.
80. Khan S, Tarzi MD, Dore PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol. 2007;123(1):14–7.
81. Rossio R, Lotta LA, Pontiggia S, Borsa Ghiringhelli N, Garagiola I, Ardissino G, et al. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica. 2015;100:e87–9. doi:10.3324/haematol.2014.111062.
82. Mohlin FC, Nilsson SC, Levart TK, Golubovic E, Rusai K, Muller-Sacherer T, et al. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol. 2015;65(2):367–76. doi:10.1016/j.molimm.2015.02.013.
83. Gulleroglu K, Fidan K, Hancer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol. 2013;28(5):827–30. doi:10.1007/s00467-013-2416-9.
84. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant. 2010;25(7):2195–202. doi:10.1093/ndt/gfq010.